Provide feedbackProvide feedback

San Antonio Breast Cancer Symposium

30th Annual SABCS

December 12-16, 2007San Antonio, Texas
VerusMed is an independent news organization and is not affiliated with the San Antonio Breast Cancer Symposium

Continuation of tamoxifen beyond standard 5 years reduces breast cancer recurrence, preliminary data show

Tuesday, December 18, 2007 | Comments

Continuation of tamoxifen beyond the current standard duration of 5 years reduces recurrence over the next few years, according to an early analysis of the latest preliminary data from the ATLAS study.

The researchers explained that despite data showing that 5 years of tamoxifen therapy substantially reduces the annual ...[more] Locked

Denosumab increases BMD in women with breast cancer receiving AI therapy, findings indicate

Monday, December 17, 2007 | Comments

Twice-yearly administration of denosumab consistently increased bone mineral density (BMD) during 24 months of treatment in women with nonmetastatic breast cancer who had low bone mass and were receiving adjuvant aromatase inhibitors (AI), data from the Phase III HALT Breast Cancer 135 study showed.

Although adjuvant ...[more] Locked

Anastrozole appears superior to tamoxifen in reducing risk of recurrence in patients with early breast cancer, data show

Monday, December 17, 2007 | Comments

Anastrozole significantly reduces the risk of recurrence as compared with tamoxifen citrate in postmenopausal women with hormone receptor (HR)-positive breast cancer, according to long-term follow-up data from the ATAC study. However, the data also revealed that anastrozole, an aromatase inhibitor (AI), is associated with a higher ...[more] Locked

Micrometastatic deposits in sentinel nodes may play role in treatment decisions, data show

Tuesday, December 18, 2007 | Comments

Micrometastatic deposits in the sentinel nodes may help to eventually define which patients should receive maximum adjuvant therapy (medical or surgical) and which patients could avoid additional therapy, according to results from a prospective study.

One of the most significant prognostic factors for patients with breast ...[more] Locked

Docetaxel plus cyclophosphamide improves overall survival better than standard chemotherapy in women with breast cancer, data show

Wednesday, December 19, 2007 | Comments

For women with early-stage breast cancer who have had surgery, treatment with the combination of docetaxel and cyclophosphamide significantly improves overall survival relative to standard chemotherapy, according to recent data.

The USO Adjuvant Trial 9735 included 1,016 patients who had surgery and then were randomized ...[more] Locked

  1. No articles have been read
  1. No articles have been emailed